Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.010
Sell
RSI(14)
42.025
Neutral
STOCH(KDJ)(9,3,3)
21.190
Sell
ATR(14)
0.447
Low Volatility
CCI(14)
-61.502
Neutral
Williams %R
72.667
Sell
TRIX(12,20)
-0.333
Sell
StochRSI(14)
0.000
Sell
Search
Solid Biosciences Inc
SLDBAdd to Watchlist
6.585USD
+0.125+1.93%
Market hours （ET）Quotes delayed by 15 min
520.00MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Solid Biosciences Inc
Currency: USD Updated: 2026-06-08Key Insights
Solid Biosciences Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 71 out of 390 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 18.50.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Solid Biosciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Solid Biosciences Inc Highlights
StrengthsRisks
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -3.34, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 83.89M shares, decreasing 14.08% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 124.27K shares of this stock.
Analyst Rating
Based on
14
analysts
Buy
Current Rating
18.500
Target Price
+176.12%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-06-08The current financial score of Solid Biosciences Inc is 6.75, ranking 217 out of 390 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.21
Operational Efficiency
2.75
Growth Potential
6.75
Shareholder Returns
7.03
Solid Biosciences Inc's Company Valuation
Currency: USD Updated: 2026-06-08The current valuation score of Solid Biosciences Inc is 6.64, ranking 232 out of 390 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.34, which is -101.58% below the recent high of 0.05 and -29.53% above the recent low of -4.33.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 71/390
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-06-08The current earnings forecast score of Solid Biosciences Inc is 8.86, ranking 41 out of 390 in the Biotechnology & Medical Research industry. The average price target is 15.00, with a high of 20.00 and a low of 9.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
14
analysts
Buy
Current Rating
18.500
Target Price
+188.61%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
558
Total
5
Median
6
Average
Company name
Ratings
Analysts
Solid Biosciences Inc
SLDB
14
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-06-08The current price momentum score of Solid Biosciences Inc is 6.97, ranking 102 out of 390 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 7.56 and the support level at 5.63, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
6.756
Sell
MA10
6.928
Sell
MA20
6.939
Sell
MA50
7.386
Sell
MA100
6.976
Sell
MA200
6.215
Buy
Institutional Confidence
Currency: USD Updated: 2026-06-08The current institutional shareholding score of Solid Biosciences Inc is 7.00, ranking 82 out of 390 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 85.25%, representing a quarter-over-quarter decrease of 19.69%. The largest institutional shareholder is Steven Cohen, holding a total of 2.05M shares, representing 2.08% of shares outstanding, with 701.81% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Perceptive Advisors LLC
RA Capital Management, LP
Invus Public Equities Advisors, LLC
Vestal Point Capital, LP
Bain Capital Life Sciences Investors, LLC
BlackRock Institutional Trust Company, N.A.
Citadel Advisors LLC
Armistice Capital LLC
Fidelity Management & Research Company LLC
1
2
Risk Assessment
Currency: USD Updated: 2026-06-08The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Solid Biosciences Inc is 3.70, ranking 117 out of 390 in the Biotechnology & Medical Research industry. The company's beta value is 2.43. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
2.43
VaR
+8.17%
240-Day Maximum Drawdown
+44.41%
240-Day Volatility
+82.56%
Return
Best Daily Return
60 days
+10.94%
120 days
+20.32%
5 years
+68.42%
Worst Daily Return
60 days
-9.31%
120 days
-11.15%
5 years
-23.66%
Sharpe Ratio
60 days
-0.68
120 days
+0.62
5 years
+0.03
Risk Assessment
Maximum Drawdown
240 days
+44.41%
3 years
+82.92%
5 years
+96.06%
Return-to-Drawdown Ratio
240 days
+0.72
3 years
+0.16
5 years
-0.17
Skewness
240 days
+0.65
3 years
+2.19
5 years
+2.15
Volatility
Realised Volatility
240 days
+82.56%
5 years
+102.18%
Standardised True Range
240 days
+7.14%
5 years
+11.40%
Downside Risk-Adjusted Return
120 days
+115.94%
240 days
+115.94%
Maximum Daily Upside Volatility
60 days
+50.85%
Maximum Daily Downside Volatility
60 days
+53.33%
Liquidity
Average Turnover Rate
60 days
+1.50%
120 days
+1.52%
5 years
--
Turnover Deviation
20 days
-31.53%
60 days
-27.65%
120 days
-26.84%
Peer Comparison
Biotechnology & Medical Research
Solid Biosciences Inc
SLDB
6.92 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.79 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
CRL
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Veracyte Inc
VCYT
8.29 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
